Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04835441
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-29
First Post:
2021-04-05
Brief Title:
ALPN-101 Acazicolcept in Systemic Lupus Erythematosus
Sponsor:
Alpine Immune Sciences Inc
Organization:
Alpine Immune Sciences Inc
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Study of ALPN-101 in Systemic Lupus Erythematosus
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Synergy
Brief Summary:
This is Phase 2 multinational randomized blinded study to evaluate the safety tolerability efficacy immunogenicity pharmacokinetics and pharmacodynamics of ALPN-101 acazicolcept in adults with moderate to severe active systemic lupus erythematosus SLE
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None